SIB 1508Y

Known as: SIB-1508Y 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2008
2008
Pharmacological characterization of (S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), a novel nicotinic acetylcholine receptor agonist
(S)-(2)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine HCl (SIB-1508Y, Altinicline), is a subtype-selective neuronal nicotinic… (More)
Is this relevant?
2006
2006
Randomized placebo-controlled study of the nicotinic agonist SIB-1508Y in Parkinson disease.
  • Neurology
  • 2006
This randomized, placebo-controlled, 5-week Phase II trial evaluated the safety and tolerability of SIB-1508Y, a selective… (More)
Is this relevant?
2000
2000
Antidepressant-like effects of the subtype-selective nicotinic acetylcholine receptor agonist, SIB-1508Y, in the learned helplessness rat model of depression
Rationale: Epidemiological studies of smokers suggest that there is a link between nicotine and depression. Nonetheless, few… (More)
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2000
2000
Recombinant human receptors and functional assays in the discovery of altinicline (SIB-1508Y), a novel acetylcholine-gated ion channel (nAChR) agonist.
Neuronal nicotinic acetylcholine receptors (nAChRs) are a class of ion channels with significant potential as molecular targets… (More)
Is this relevant?
1999
1999
Nicotinic acetylcholine receptor agonist SIB-1508Y improves cognitive functioning in chronic low-dose MPTP-treated monkeys.
Monkeys that receive chronic low-dose 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridine (MPTP) administration have difficulty… (More)
Is this relevant?
1999
1999
Nicotinic Acetylcholine Receptor Agonist SIB-1508 Y Improves Cognitive Functioning in Chronic Low-Dose MPTP-Treated Monkeys 1
Monkeys that receive chronic low-dose 1-methyl-4-phenyl1,2,3,6-tetrahydropyridine (MPTP) administration have difficulty… (More)
  • figure 2
  • figure 1
  • figure 3
  • figure 4
  • table 1
Is this relevant?
1998
1998
Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys.
The potential antiparkinsonian effects of the centrally acting, subtype-selective neuronal nicotinic acetylcholine receptor… (More)
Is this relevant?
Review
1998
Review
1998
Effects of the nicotinic acetylcholine receptor agonist SIB-1508Y on object retrieval performance in MPTP-treated monkeys: comparison with levodopa treatment.
This study assessed the relative potencies of levodopa/benserazide and the nicotinic acetylcholine receptor agonist SIB-1508Y on… (More)
Is this relevant?
Review
1998
Review
1998
The potential of subtype-selective neuronal nicotinic acetylcholine receptor agonists as therapeutic agents.
Neuronal nicotinic acetylcholine receptors (NAChRs) are pentameric ligand-gated ion channel receptors which exist as different… (More)
Is this relevant?
1996
1996
(S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors.
 
Is this relevant?